ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2017
Long-term outcome of 487 patients with early-stage extra-nodal marginal zone lymphoma.
Article in Annals of oncology : official journal of the European Society for Medical Oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 79 citations in OpenAlex.
- Trial
- Article
- Marginal B-cell lymphoma: A 10-year retrospective study at national institute of hematology and blood transfusion, Vietnam.SAGE open medicine · 2025Article
- Long-term survival outcomes of 'watch and wait' in patients with bronchus-associated lymphoid tissue lymphoma: a multicenter real-world data analysis in Korea.Annals of hematology · 2024Article
- Should All Patients With Stage IE Gastric Mucosa-Associated Lymphoid Tissue Lymphoma Receive Antibiotic Eradication Therapy forJCO oncology practice · 2024Article
- Treatment and survival for patients with localized primary ocular adnexal extranodal marginal zone lymphoma.Leukemia · 2024Article
- Non-resolving pneumonia: primary pulmonary MALT lymphoma.BMJ case reports · 2024Article
- China Anti-Cancer Association Guidelines for the diagnosis, treatment, and follow-up of thymic epithelial tumors (2023).Mediastinum (Hong Kong, China) · 2024Review
- Article
- Very low-dose radiotherapy for extranodal marginal zone lymphoma of bronchus-associated lymphoid tissue.Leukemia & lymphoma · 2023Article
- Clinical Management of Patients with Gastric MALT Lymphoma: A Gastroenterologist's Point of View.Cancers · 2023Review
- Multi-omics and case-control analyses identify immunoglobulin M as a tumour-derived serum biomarker of ocular adnexal extranodal marginal zone lymphoma.Clinical and translational medicine · 2023Article
- Predictors of survival in patients with MALT lymphoma: a retrospective, case-control study.Blood advances · 2023Review
- Intestinal Mucosa-Associated Lymphoid Tissue Lymphoma Transforming into Diffuse Large B-Cell Lymphoma in a Young Adult Patient with Neurofibromatosis Type 1: A Case Report.Medicina (Kaunas, Lithuania) · 2022Article
- Primary pulmonary mucosa-associated lymphoid tissue lymphoma: A case report.Radiology case reports · 2022Article
- Article
- Revised MALT-IPI: A new predictive model that identifies high-risk patients with extranodal marginal zone lymphoma.American journal of hematology · 2022Article
- An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma.Blood advances · 2022Article
- Review
- Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma in the Gastrointestinal Tract in the Modern Era.Cancers · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundLocalized early-stage extra-nodal marginal zone lymphoma (MZL) presents with heterogeneous organ involvement and is treated with various modalities, including resection, radiotherapy, and systemic therapy. We report the long-term outcome of a large cohort of extra-nodal MZL and assess the impact of patient and disease characteristics, organ site, and treatment strategy on disease control and survival. PATIENTS AND
methodsWe identified 487 consecutive patients with stage IE or IIE MZL referred between 1992 and 2012 to Memorial Sloan Kettering Cancer Center. Pathology was reviewed by hematopathologists at our institution. Patient and disease factors as well as treatment types were analyzed for association with relapse-free survival, overall survival, and cumulative incidence of relapse.
resultsMedian follow-up after treatment was 4.7 years. Five-year relapse-free survival and overall survival were 60% and 89%, respectively. Cumulative incidence of disease-specific death at 5 years was 1.3%. Radiotherapy alone was the initial treatment in 50% of patients, followed by surgical resection (30%), observation (8%), immunotherapy (4%), and chemotherapy (2%). Initial treatment type, primary disease site, and number of involved sites were significant factors in multivariable analysis of relapse (all P < 0.05). When compared with stomach, MZL originating in other disease sites (HR > 2.0, P ≤ 0.001), except for thyroid, had higher risk of relapse. Strategies such as antibiotics or topical therapies were associated with higher risk of relapse when compared with radiation therapy (P < 0.001). Crude rate of transformation to pathologically confirmed large-cell lymphoma was 2% (11 patients).
conclusionOverall and cause-specific survival are high in early-stage extra-nodal MZL. Curative-intent treatment led to fewer relapses and reduced the need for salvage. Stomach cases had lower risk of relapse than other anatomic primary sites. This study supports the use of local therapies to treat stage IE and IIE MZL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.